What is AngioDynamics's gross profit margin?

What is the revenue and EPS growth rate for AngioDynamics year over year?

What is AngioDynamics's latest dividend and current dividend yield?

What factors drove the changes in AngioDynamics's revenue and profit?

What were the key takeaways from AngioDynamics’s earnings call?

What does AngioDynamics do and what are its main business segments?

What guidance did AngioDynamics's management provide for the next earnings period?

What is the market's earnings forecast for AngioDynamics next quarter?

- **12.2% Revenue Growth**: Med Tech segment up 26.1% to $35.3 million, driven by Auryon (+20.1%), AlphaVac (+52.3%), and NanoKnife (+26.7%).
- **Gross Margin Expansion**: 55.3% (up 90 bps) despite $1.7M tariffs, with operational efficiency gains.
- **Updated Guidance**: FY26 revenue raised to $308-313M, Med Tech +14-16%, and EBITDA guidance to $6-10M.
- **Sales Force Expansion**: 25% increase in Mechanical Thrombectomy reps to 50, targeting BTK and coronary market expansion.
- **CPT Code Impact**: NanoKnife prostate treatment CPT code effective Q3, with AARP ad campaign driving patient awareness.
- **Clinical Momentum**: AMBITION BTK study enrollment on track, supporting Auryon's BTK leadership.


**【CEO Summary Section】**
- **Revenue Growth**: Q1 revenue increased 12.2% to $75.3 million, driven by a 26.1% surge in the Med Tech segment to $35.3 million and 2.3% growth in the Med Device segment to $40.4 million.
- **Auryon Performance**: Auryon revenue rose 20.1% to $16.5 million, marking 17 consecutive quarters of double-digit growth, with international expansion contributing $500,000.
- **Mechanical Thrombectomy**: Combined AngioVac and AlphaVac revenue jumped 41.2% to $11.3 million, with AlphaVac up 52.3%.
- **NanoKnife Expansion**: Revenue climbed 26.7% to $6.4 million, driven by the expanded prostate indication and upcoming CPT code in Q3.
- **Gross Margin**: Improved 90 basis points to 55.3%, despite $1.7 million in tariffs, with operational efficiency gains.
- **Guidance Update**: Full-year revenue raised to $308-$313 million (5-7% growth), Med Tech up 14-16%, and adjusted EBITDA guidance increased to $6-10 million.

**【CFO Financial Commentary】**
- **Segment Breakdown**: Med Tech now 47% of total revenue vs. 41% last year, reflecting strategic shift. Med Tech CAGR 25% since 2020.
- **Tariff Impact**: Expect $4-6 million annually, with Q1 at $1.7 million. Gross margin initiatives ahead of schedule.
- **Operating Efficiency**: Total expenses at 69.4% of sales vs. 74% last year, with R&D at 8.5% and SG&A at 53.7%.
- **Cash Flow**: Q1 cash utilization $38.8 million vs. $55.9 million last year, targeting FY26 cash flow positive.

**【Q&A Highlights】**
- **Sales Force Expansion**: Mechanical Thrombectomy team expanded 25% to 50 reps, mirroring Auryon's successful 5-year build-out.
- **NanoKnife Reimbursement**: CPT code effective Jan 2026, with urology adoption accelerating post-campaign launch.
- **Clinical Trials**: AMBITION BTK study enrollment on track, with Auryon's unique design driving BTK market share growth.
- **Revenue Mix**: 47% Med Tech vs. 41% last year, with pricing and utilization driving mechanical thrombectomy growth.


ANGO

ANGO fundamentals

You can ask Aime